Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
2.200
+0.100 (4.76%)
Dec 20, 2024, 4:00 PM EST - Market closed
Alterity Therapeutics Employees
Alterity Therapeutics had 10 employees as of June 30, 2024. The number of employees decreased by 1 or -9.09% compared to the previous year.
Employees
10
Change (1Y)
-1
Growth (1Y)
-9.09%
Revenue / Employee
$268,167
Profits / Employee
-$1,275,918
Market Cap
18.30M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Flora Growth | 108 |
Bolt Biotherapeutics | 100 |
BioLineRx | 79 |
Senti Biosciences | 48 |
Palatin Technologies | 30 |
Bullfrog AI | 11 |
CervoMed | 8 |
Tenax Therapeutics | 6 |
ATHE News
- 17 days ago - Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy - GlobeNewsWire
- 4 weeks ago - Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary - GlobeNewsWire
- 5 weeks ago - Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium - GlobeNewsWire
- 6 weeks ago - Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434 - GlobeNewsWire
- 7 weeks ago - Appendix 4C – Q1 FY25 Quarterly Cash Flow Report - GlobeNewsWire
- 2 months ago - Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024 - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders® - GlobeNewsWire